Vor Biopharma (VOR) shares were down 1.2% in Tuesday trading after the company reported its Q2 results.
The company reported a Q2 net loss of $1.16 per diluted share, narrower than a loss of $251.24 a year earlier.
Analysts polled by FactSet expected a loss $0.70.
As of June 30, the company said it had $466.1 million in cash, cash equivalents and marketable securities, which it expects to fund operations through early 2029 taking into account $48.4 million net proceeds from at-the-market sales during July.
Price: 23.13, Change: -0.24, Percent Change: -1.03
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments